A preliminary clinical study at Johns Hopkins Kimmel Cancer Center demonstrated that antibody treatment could decrease by half the…
Timea Polgar
Timea is a Molecular biologist (MSc) & Computational chemist (MSc, PhD), science liaison, and strategic business development and marketing specialist, with 15 years in pharmaceutical R&D, biotech and scientific software development.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Timea Polgar
The diagnosis and management of myeloma in the very elderly is especially challenging, despite improvements in therapies. A review study, “…